Dyslipidemia News and Research

RSS

Dyslipidemia is a disruption in the amount of lipids in the blood.

Dr. Reddy’s initiates DRL-17822 Phase II study in type II dyslipidemia

Dr. Reddy's Laboratories announced the initiation of dosing with DRL-17822 in patients with diagnosis of type II dyslipidemia. DRL-17822 is a selective, orally bioavailable inhibitor of cholesteryl ester transfer protein (CETP), for the treatment and/or prevention of dyslipidemia, atherosclerosis and associated cardiovascular disease.

2 Sep 2011

FDA grants Fast Track designation for DARA's KRN5500 neuropathic pain relief drug

DARA BioSciences, Inc. announced today that its investigational drug KRN5500 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of chemotherapy-induced neuropathic pain in patients with cancer.

19 Aug 2011

Enrollment commences in Omthera's Epanova Phase III trial for hypertriglyceridemia

Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that the first patient has been enrolled in its ESPRIT Phase III clinical trial of Epanova, in patients with hypertriglyceridemia (TG level greater than or equal to 200 and < 500 mg/dL) despite treatment with a statin.

16 Aug 2011

Positive data from two GSK's Promacta Phase III studies on hepatitis C-related thrombocytopenia

Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has announced that it received positive data from ENABLE-1, the first of two Phase III studies examining Promacta in patients with hepatitis C-related thrombocytopenia, and that full data will be released at an upcoming scientific conference.

27 Jul 2011

InVasc commences INV-144 Phase IIa trial in chronic kidney disease

InVasc Therapeutics, Inc., announced today that it has initiated a Phase IIa, proof of concept (POC), clinical trial with INV-144, a combination drug of losartan with alpha Lipoic Acid (ALA), to slow the progression of chronic kidney disease (CKD) in hypertensive diabetic patients.

24 Jun 2011

Ligand's LGD-4033 Phase I clinical trial data presented at the Endocrine Society annual meeting

Ligand Pharmaceuticals Incorporated today announced that data from a comprehensive Phase I multi-dose program with its selective androgen receptor modulator (SARM) LGD-4033 was featured in a poster presentation today at the Endocrine Society Annual Meeting in Boston, June 4-7, 2011.

7 Jun 2011

Preclinical study: Combination therapy of SPX-106 and D-tagatose reduces triglycerides and cholesterol

Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its drug candidate, SPX-106, achieved statistically significant reductions in triglycerides and cholesterol when administered in combination with D-tagatose for nine weeks to genetically engineered mice prone to dyslipidemia.

3 Jun 2011

Efficacy of Abbott cholesterol drug in question

A latest study has found that using medication to raise good cholesterol while lowering the bad does NOT translate into fewer adverse cardiovascular events like heart attacks and strokes. The study was revealed Thursday by the National Institutes of Health and it found that high dosages of Abbott Laboratories' Niaspan failed to prevent heart attacks and boosted the likelihood of a stroke when combined with the popular generic cholesterol pill Simvastatin, also known under the brand name Zocor.

29 May 2011

Interim analysis of AIM-HIGH study affirms positive impact of Niaspan on HDL and triglyceride lipid values

The National Heart, Lung and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), disclosed results from an interim analysis of the AIM-HIGH clinical trial.

27 May 2011

GE Healthcare receives FDA 510k clearance for CoreScan to treat obesity-related disease

GE Healthcare today announced 510k clearance of CoreScan - a widely-accessible application dedicated to quickly and accurately quantifying visceral adipose tissue, or visceral "belly" fat, during body composition analysis.

26 May 2011

Archimedes launches new web interface, ARCHeS Innovator

Archimedes Inc., a healthcare modeling company, today announced the launch of a new web interface, ARCHeS Innovator, which will give health experts direct access to many of the features of the Archimedes Model.

23 May 2011

Abbott appreciates FDA Advisory Committee recommendations to retain Trilipix indication for mixed dyslipidemia

The U.S. Food and Drug Administration today held an Endocrinologic and Metabolic Drugs Advisory Committee to review the results of the ACCORD Lipid study as they relate to the use of fenofibric acid (sold as Trilipix in the United States) in combination with a statin in patients with mixed dyslipidemia and at high risk of heart disease.

20 May 2011

Metabolex commences arhalofenate Phase 2 clinical trial for treatment of hyperuricemia and gout

Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced that it has initiated a Phase 2 clinical trial of arhalofenate (MBX-102), its product candidate for the management of hyperuricemia in patients with gout.

19 May 2011

Esperion reports positive results from ETC-1002 Phase 1 study in dyslipidemia

Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced the results from a Phase 1 study and four preclinical studies for ETC-1002 at the Arteriosclerosis, Thrombosis and Vascular Biology 2011 Scientific Sessions in Chicago.

3 May 2011

Watson launches Generess Fe low-dose oral contraceptives in the U.S.

Watson Pharmaceuticals, Inc., today announced the U.S. commercial launch of Generess Fe 0.8 mg/25 mcg, a new low-dose oral contraceptive option that's highly effective at preventing pregnancy and proven to provide users with short, lighter, predictable periods.

2 May 2011

Merck first quarter sales increase 1% to $11.6 billion for 2011

Merck, known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2011.

30 Apr 2011

Melatonin can help fight obesity and risks associated with it

University of Granada researchers have proven that melatonin -a natural hormone produced by the body- helps in controlling weight gain -even without reducing the intake of food-, improves blood lipid profile -as it reduces triglicerids-, increases HDL cholesterol and reduces LDL cholesterol.

29 Apr 2011

Legislative approaches needed to address obesity epidemic in Canada

With the increase in numbers of overweight children and young adults, Canada and other developed countries are facing an obesity epidemic and legislative approaches are required to address this issue, states an article in CMAJ (Canadian Medical Association Journal).

28 Apr 2011

Alkem, Karo Bio partner to license eprotirome

Karo Bio has entered into a collaboration and license agreement with the Indian pharmaceutical company Alkem Laboratories Ltd.

26 Apr 2011

Prism Pharmaceuticals to be acquired by Baxter

Ligand Pharmaceuticals Incorporated announced that its partner Prism Pharmaceuticals has entered into a definitive agreement to be acquired by Baxter International Inc.. Prism Pharmaceuticals recently received FDA approval for Nexterone®, an antiarrhythmic agent which Ligand (through its CyDex Pharmaceuticals subsidiary) originally developed with its patented Captisol® formulation technology and licensed to Prism in 2006.

From Baxter International Inc. 20 Apr 2011